Accueil › Cancer colorectal › Colorado › Denver
Essais cliniques pour Cancer colorectal à Denver, CO
23 études pour Cancer colorectal recherchent des participants dans et autour de Denver (dans un rayon d'environ 30 miles). Ouvrez une étude pour voir qui peut participer et comment contacter l'équipe.
Texte officiel de l'étude (anglais)
Vous recrutez pour une étude ? Mettez-la en avant en haut de cette page — $99 pour 30 jours →
The Vanguard Study: Testing a New Way to Screen for Cancer
Recrutement en coursVolontaires sains bienvenus
- Kaiser Permanente-Franklin, Denver
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Recrutement en coursPhase 1/2
- Rocky Mountain Cancer Center, Denver
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Recrutement en coursÉtude observationnelleVolontaires sains bienvenus
- AdventHealth Porter, Denver
Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer
Recrutement en coursPhase 3
- Intermountain Health Cancer Center Saint Joseph, Denver
- Intermountain Health Saint Joseph Hospital - Research Office, Denver
- Intermountain Health Saint Joseph Hospital, Denver
- et 3 autres
Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or Targeted Therapy and/or ICI, for the Treatment of Patients With Advanced Gastrointestinal Cancers, Including Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)
Recrutement en coursPhase 1/2
- Sarah Cannon Research Institute (SCRI), Denver
A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy
Recrutement en coursPhase 3
- Rocky Mountain Cancer Centers, Denver
A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
Recrutement en coursPhase 3
- Rocky Mountain Cancer Centers, Denver
A Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker CA19-9
Recrutement en coursPhase 1/2
- SCRI at HCA Health One, Denver
A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer
Recrutement en coursPhase 1
- SCRI Denver, Denver
MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors
Recrutement en coursPhase 1
- Sarah Cannon Research Institute at HealthOne, Denver
A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors
Recrutement en coursPhase 1
- Sarah Cannon Research Institute, Denver
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
Recrutement en coursPhase 1/2
- Rocky Mountain Cancer Center, Denver
- Sarah Cannon Research Institute at HealthONE, Denver
A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
Recrutement en coursPhase 1
- Sarah Cannon Research Institue At Healthone, Denver
A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer
Recrutement en coursPhase 3
- Rocky Mountain Cancer Centers, LLP, Denver
- Rocky Mountain Cancer Centers, LLP, Denver
A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types
Recrutement en coursPhase 1
- Sarah Cannon Research Institute at HealthONE, Denver
CT-95 in Advanced Cancers Associated With Mesothelin Expression
Recrutement en coursPhase 1
- Context Investigational Site, Denver
A Study of Fruquintinib Plus FOLFIRI as Second-Line Treatment for Participants With Metastatic Colorectal Cancer (FRUITFUL)
Recrutement en coursPhase 2
- Rocky Mountain Cancer Center - Primary, Denver
KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors
Recrutement en coursPhase 1
- Sarah Cannon Research Institute at HealthONE, Denver
Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions
Recrutement en coursPhase 1/2
- SCRI - Denver, Denver
Exogenous and Endogenous Risk Factors for Early-onset Colorectal Cancer
Recrutement en coursÉtude observationnelleVolontaires sains bienvenus
- Department of Medicine-Gastroenterology, Denver Veterans Affairs Medical Center, University of Colorado Hospital, Denver
A Study to Investigate the Safety and Efficacy of KQB365 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies
Recrutement en coursPhase 1
- Sarah Cannon Cancer Institute at HealthONE, Denver
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
Recrutement en coursÉtude observationnelle
- Kaiser Permanente-Franklin, Denver
- Colorado Blood Cancer Institute, Denver
- Rocky Mountain Cancer Centers-Midtown, Denver
- et 1 autres
Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors
Recrutement en coursPhase 1/2
- Sarah Cannon Research Institute at HealthONE, Denver
Essais pour Cancer colorectal dans d'autres villes
- Houston, TX102 études
- New York City, NY78 études
- Nashville, TN69 études
- Boston, MA63 études
- Los Angeles, CA59 études
- Arlington, VA52 études
- St. Louis, MO50 études
- San Antonio, TX46 études
- Philadelphia, PA44 études
- Grand Rapids, MI40 études
- Baldwin Park, CA37 études
- Chicago, IL34 études
Autres études à Denver
- Cancer métastatique29 études
- Cancer du sein29 études
- Cancer du poumon non à petites cellules27 études
- Myélome multiple27 études
- Mélanome19 études
- Cancer de la prostate19 études
- Cancer (tous types)18 études
- Cancer de l'ovaire16 études
- Cancer du poumon16 études
- Cancer de l'endomètre15 études
- Lymphome non hodgkinien14 études
- Cancer du pancréas13 études
Source : ClinicalTrials.gov, données récupérées le 6 oct. 2026. Chaque étude définit ses propres critères d'éligibilité ; l'équipe de l'étude décide qui peut y participer.